References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

10.31146/1682-8658-ecg-212-4-86-92

nogr-2366

Research Article

КЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯ

CLINICAL GASTROENTEROLOGY

Калий-конкурентные ингибиторы протонной помпы - состояние и перспективы использования

Competitive proton pump inhibitors - status and Prospects of use

https://orcid.org/0000-0002-7359-0238

Ортенберг

Э. А.

Ortenberg

E. A.

edort72@gmail.com

https://orcid.org/0000-0002-9608-2746

Ляпина

М. В.

Lyapina

M. V.

noemail@neicon.ru

https://orcid.org/0000-0001-7203-5729

Дороднева

Е. Ф.

Dorodnyeva

E. F.

noemail@neicon.ru

Федеральное государственное бюджетное образовательное учреждение высшего образования «Тюменский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияTyumen State Medical University of the Ministry of Health of the Russian FederationRussian Federation

2023

26072023

048692

2023

Ортенберг Э.А., Ляпина М.В., Дороднева Е.Ф.

Ortenberg E.A., Lyapina M.V., Dorodnyeva E.F.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/2366

Цель. Суммировать оценки влияния использования калий-конкурентных ингибиторов протонной помпы в алгоритмах фармакотерапии пациентов с язвенной болезнью, ГЭРБ на результаты лечения. Материал и методы. Проанализированы наиболее масштабные (как правило) публикации последнего пятилетия, посвященные рассматриваемой проблеме. Поиск проводился по ключевым словам в информационной базе Pubmed (ncbi.nlm.nih.gov). Выводы. Калий-конкурентные кислотные блокаторы (К-ККБ), по сравнению с «традиционными» препаратами этого класса (ингибиторы протонной помпы) обладают преимуществами с клинических и фармакоэкономических позиций как при язвенной болезни (в частности, в рамках эрадикационной терапии), так и при гастро-эзофагальной рефлюксной болезни. Подтверждение этих данных в условиях использования К-ККБ у пациентов РФ представляется целесообразным.

Purpose. To summarize the estimates of the effect of the use of potassium-competitive proton pump inhibitors in pharmacotherapy algorithms for patients with peptic ulcer disease, GERD on treatment outcomes. Material and methods. The most large-scale (as a rule) publications of the last five years devoted to the problem under consideration are analyzed. The search was carried out by keywords in the Pubmed information database (ncbi.nlm.nih.gov). Findings. Potassium-competitive acid blockers (P-CABs), in comparison with «traditional» drugs of this class (proton pump inhibitors), have advantages from a clinical and pharmacoeconomic point of view both in peptic ulcer disease (in particular, as part of eradication therapy) and in gastro-esophageal reflux disease. Confirmation of these data in the conditions of use of K-CCB in patients of the Russian Federation seems appropriate.

вонопразантегопразанкалий-конкурентные кислотные блокаторыэрадикационная терапияГЭРБ

vonoprazantegoprazanpotassium-competitive acid blockerseradication therapyGERD

References1

Maev I.V., Andreev D. N., Dicheva D. E., Goncharenko A. Yu. Pharmacotherapeutic aspects of the use of proton pump inhibitors. Medical Bulletin of the Ministry of Internal Affairs. 2013; 3(64): 9-14. (In Russ.)@@ Маев И. В., Андреев Д. Н., Дичева Д. Е., Гончаренко А. Ю. Фармакотерапевтические аспекты применения ингибиторов протонной помпы. Медицинский вестник МВД. 2013; 3(64): 9-14.

Mori H., Suzuki H. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. J Neurogastroenterol Motil. 2019; 25(1): 6-14. doi: 10.5056/jnm18139.

Lee K.N., Lee O. Y., Chun H. J. et al. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World J Gastroenterol. 2022; 28(44):6294-6309. doi: 10.3748/wjg.v28.i44.6294.

Engevik A.C., Kaji I., Goldenring J. R. The Physiology of the Gastric Parietal Cell. Physiol Rev. 2020; 100(2): 573-602. doi: 10.1152/physrev.00016.2019.

Kiyotoki S., Nishikawa J., Sakaida I. Efficacy of Vonoprazan for Helicobacter pylori Eradication.Intern Med. 2020; 59(2): 153-161. doi: 10.2169/internalmedicine.2521-18.

Shibli F., Kitayama Y., Fass R. Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors. Curr Gastroenterol Rep. 2020; 22(4):16. doi: 10.1007/s11894-020-0753-y.

Leowattana W., Leowattana T. Potassium-competitive acid blockers and gastroesophageal reflux disease. World J Gastroenterol. 2022; 28(28): 3608-3619. doi: 10.3748/wjg.v28.i28.3608.

Jenkins H., Sakurai Y., Nishimura A. et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015; 41(7): 636-648. doi: 10.1111/apt.13121.

Sugimoto M., Yamaoka Y. Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Front Pharmacol. 2018; 9: 1560. doi: 10.3389/fphar.2018.01560.

Miwa H., Igarashi A., Teng L. et al. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease. J Gastroenterol. 2019; 54(8): 718-729. doi: 10.1007/s00535-019-01572-y.

New drug approved for market in China in 2019: TAK-438, Vonoprazan fumarate [Internet]. Available from: https://www.chinazerchem.com/news/characteristics-of-food-additives-27520879.html

Iwakiri K., Fujiwara Y., Manabe N. et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022; 57(4): 267-285. doi: 10.1007/s00535-022-01861-z.

Zhang M., Pang M., Zhang M. Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials. Clinics (Sao Paulo). 2022; 77: 100058. doi: 10.1016/j.clinsp.2022.100058.

Shinozaki S., Kobayashi Y., Osawa H.et al. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis. Digestion. 2021; 102: 319-325. doi: 10.1159/000504939.

Kim S.Y., Chung J-W. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics (Basel). 2020; 9(8): 436. doi: 10.3390/antibiotics9080436.

Mori H., Suzuki H. Update on quinolone-containing rescue therapies for Helicobacter pylori infection. World J Gastroenterol. 2020; 26(15): 1733-1744. doi: 10.3748/wjg.v26.i15.1733.

Wang S-W., Yu F-J.,, Kuo F-C. et al., Rescue therapy for refractory Helicobacter pylori infection: current status and future concepts. Therap Adv Gastroenterol. 2023;16:17562848231170941. doi: 10.1177/ 17562848231170941.

Mizokami Y., Oda K., Funao N. et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018; 67(6): 1042-1051. doi: 10.1136/gutjnl-2017-314010.

Marabotto E., Ziola S., Savarino V. et al.Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data. Clin Exp Gastroenterol. 2020; 13: 99-104. doi: 10.2147/CEG.S228352.

Chey W.D., Mégraud F., Laine L. et al. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology. 2022; 163: 608-619.

Laine L., DeVault K., Katz P et al. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial. Gastroenterology. 2023;164(1):61-71. doi: 10.1053/j.gastro. 2022.09.041.

Zhang W-L., Lin B-S., Li Y-Y et al. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis. Digestion. 2023;1-13. doi: 10.1159/ 000529622.

Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69:1019-1026. doi: 10.1136/gutjnl-2019-319954.

Simadibrata D. M., Syam A. F., Lee Y. Y. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022; 37(12): 2217-2228. doi: 10.1111/jgh.16017.

Yang X., Li., Sun Y. et al. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Gastroenterology. 2023;164(1):61-71. doi: 10.1053/j.gastro.2022.09.041.

Xu X., He C., Zhu Y. Treatment of refractory Helicobacter pylori infection: A new challenge for clinicians. Front Microbiol. 2022; 13: 998240. doi: 10.3389/fmicb. 2022.998240.

Hirai A, Takeuchi T, Takahashi Y, et al.Comparison of the Effects of Vonoprazan and Lansoprazole for Treating Endoscopic Submucosal Dissection-Induced Artificial Ulcers. Dig Dis Sci. 2018;63(4):974-81. doi: 10.1007/s10620-018-4948-0.

He H-S., Li B-Y., Chen Q-T. et al.Comparison of the Use of Vonoprazan and Proton Pump Inhibitors for the Treatment of Peptic Ulcers Resulting from Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis. Med Sci Monit. 2019; 25: 1169-1176. doi: 10.12659/MSM.911886.

Jiang X., Li J., Xie J. et al. Histamine2-Receptor Antagonists, Proton Pump Inhibitors, or Potassium-Competitive Acid Blockers Preventing Delayed Bleeding After Endoscopic Submucosal Dissection: A Meta-Analysis. Front Pharmacol. 2019;10:1055. doi: 10.3389/fphar.2019.01055.

Martin, Zhou Y., Meng C-X. et al. Vonoprazan vs proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding A meta-analysis of randomized controlled trials and observational studies. Medicine (Baltimore). 2020; 99(9): e19357. doi: 10.1097/MD.0000000000019357.

Hidaka Y., Imai T., Inaba T. et al. Efficacy of vonoprazan against bleeding from endoscopic submucosal dissection-induced gastric ulcers under antithrombotic medication: A cross-design synthesis of randomized and observational studies. PLoS One. 2021; 16(12): e0261703. doi: 10.1371/journal.pone.0261703.

Ichida T., Ueyama S., Eto T. et al. Randomized Controlled Trial Comparing the Effects of Vonoprazan Plus Rebamipide and Esomeprazole Plus Rebamipide on Gastric Ulcer Healing Induced by Endoscopic Submucosal Dissection.Intern Med. 2019; 58(2):159-166. doi: 10.2169/internalmedicine.1146-18.

Komori H., Ueyama H., Nagahara A. et al. A prospective randomized trial of a potassium competitive acid blocker vs proton pump inhibitors on the effect of ulcer healing after endoscopic submucosal dissection of gastric neoplasia. J Int Med Res. 2019; 47(4):1441-1452. doi: 10.1177/0300060519828514.

Miao T., Zhang Y., Bai L. et al. Vonoprazan vs. Lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis. Rev Esp Enferm Dig. 2023; 115(4):168-174. doi: 10.17235/reed.2022.8863/2022.

Oshima T., Miwa H. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. J Neurogastroenterol Motil. 2018; 24(3):334-344. doi: 10.5056/jnm18029.

Moraes-Filho J.P., Domingues G., Chinzon D. et al. Vonoprazan in the management of gastric/peptic ulcers: a systematic review of safety data. Prz Gastroenterol. 2022; 17(4): 266-273. doi: 10.5114/pg.2022.112777.

Zhang M., Xiao Y., Chen M. The role of vonoprazan in patients with erosive esophagitis. Therap Adv Gastroenterol. 2022; 15: 345-358. doi: 10.1177/17562848221122623.

Habu Y. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.Intern Med. 2019; 58(17): 2427-2433. doi: 10.2169/internalmedicine.2535-18.

Scarpignato C, Hunt RH. Editorial: potassium-competitive acid blockers for acid-related diseases-tegoprazan, a new kid on the block. Aliment Pharmacol Ther. 2019;50(8):960-962. doi: 10.1111/apt.15480.

Cho Y.K., Choi M., Choi S. C. et al.Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment Pharmacol Ther. 2020;52(5):789-797. doi: 10.1111/apt.15865.

Lee K.J., Son B. K., Kim G. H. et al. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019; 49(7): 864-872. doi: 10.1111/apt.15185.

Choi Y.J., Lee Y. C., Kim J. M. et al. Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial. Gut Liver. 2022; 16(4): 535-546. doi: 10.5009/gnl220055.

Yang E., Kim S., Kim B. et al. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. Br J Clin Pharmacol. 2022; 88(7): 3288-3296. doi: 10.1111/bcp.15268.

Cho Y. K., Kim J. H., Kim H. S. et al. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. Aliment Pharmacol Ther. 2023; 57(1): 72-80. doi: 10.1111/apt.17255.

Miftahussurur M., Putra B. P., Yamaoka Y. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals (Basel). 2020; 13(10): 276. doi: 10.3390/ph13100276.

The authors declare that there are no conflicts of interest present.